Abstract：Objective To explore the clinical effect of Tacrolimus replacement therapy for non-severe aplastic anemia with Cyclosporine A intolerance.Methods The clinical data of 60 patients with non-severe aplastic anemia with Cyclosporine A intolerance admitted to our hospital from January 2017 to February 2018 were retrospectively analyzed,they were divided into treatment group A (20 cases) and treatment group B (40 cases) according to different therapeutic effects.In group A, Tacrolimus was effective when Cyclosporine A was ineffective, but in group B, Tacrolimus was still effective when Cyclosporine A was effective.The levels of hemoglobin, leukocyte and platelet before and after replacement and the occurrence of adverse reactions in 60 patients before and after replacement were compared between the two groups.Results There were no significant differences in the levels of hemoglobin, white blood cells and platelets between the two groups before and after replacement (P>0.05).The levels of hemoglobin, leukocyte and platelet in the two groups after replacement were higher than those before replacement, the differences were statistically significant(P<0.05).The incidence of renal function injury, nerve function injury and gingival hyperplasia in 60 patients after replacement was lower than that before replacement, the differences were statistically significant (P<0.05).There was no significant difference in the incidence of liver function injury and gastrointestinal reaction between 60 patients before and after replacement (P>0.05).Conclusion Tacrolimus replacement therapy for non-severe aplastic anemia patients with Cyclosporine A intolerance has better clinical effect and fewer adverse reactions, which is worthy of clinical application.
京公网安备 11010502046607号